ValiRx plc (GB:VAL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ValiRx PLC’s subsidiary, Inaphaea BioLabs, has secured a significant contract with Amply Discovery Limited to provide cell-based assays for evaluating siRNA targets in breast cancer treatment. The deal, potentially worth over £100,000, marks a strategic partnership and showcases Inaphaea’s comprehensive service capabilities. This collaboration underscores ValiRx’s commitment to advancing cancer therapeutics and women’s health solutions.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.